Related Experiment Video
Updated: Jul 4, 2026
07:33
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Published on: May 21, 2010
An update on inherited ataxias
Tanja Schmitz-Hübsch1, Thomas Klockgether
1Department of Neurology, University Clinic Bonn, Bonn, Germany.
Current Neurology and Neuroscience Reports
|July 2, 2008
Summary
Recent advances in inherited ataxias include new mutations and molecular insights, leading to revised classifications. Research is progressing towards tailored or broad therapeutic strategies and improved clinical assessments.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Inherited ataxias represent a heterogeneous group of neurodegenerative disorders.
- Recent discoveries have expanded the known spectrum of causative mutations.
- Understanding molecular pathology is crucial for classification and treatment.
Purpose of the Study:
- To provide an overview of recent advances in inherited ataxias.
- To discuss the evolving classification based on pathogenetic pathways.
- To explore emerging treatment principles and clinical trial advancements.
Main Methods:
- Literature review of recent studies on inherited ataxias.
- Analysis of newly identified causative mutations and their impact.
- Evaluation of molecular pathology findings and their implications for classification.
- Review of clinical assessment instruments and therapeutic trial outcomes.
Main Results:
- Discovery of novel mutations broadening the diagnostic landscape of ataxias.
- Advancements in understanding the molecular basis of these disorders.
- Development of a pathogenetic pathway-based classification system.
- Emergence of new clinical assessment tools for interventional trials.
- Positive results from a Phase 2 trial of idebenone for Friedreich's ataxia.
Conclusions:
- Inherited ataxia research is rapidly advancing, with new genetic and molecular insights.
- Classification is shifting towards pathogenetic mechanisms, influencing therapeutic strategies.
- While some treatments may be broadly applicable, others may require disorder-specific approaches.
- Clinical trial readiness is improving, offering hope for effective interventions, particularly for Friedreich's ataxia.
Related Concept Videos
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...